

AlzeCure Pharma to present at Stora Aktiedagarna in Stockholm on June 10

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the company's CEO Martin Jönsson will present at Stora Aktiedagarna in Stockholm, Sweden, hosted by Aktiespararna, at 08:50 CET on June 10.

In his presentation, Martin Jönsson will highlight the company's project portfolio and drug candidates from the research platforms NeuroRestore[®], Alzstatin[®] and Painless. The presentation will be followed by a Q&A led by Aktiespararna's moderator.

The live broadcast is available via the following link: <https://invitepeople.com/public/events/bb6e31a6f2/pages/bb79be3286>

The presentation will also be available on the company's website afterwards: <https://www.alzecurepharma.se/en/presentations-and-interviews/>

For more information about the event and to register to attend the Birger Jarl Conference in Stockholm, please see here: <https://invitepeople.com/events/bb6e31a6f2>

Event time: June 10, 08:00 CET – June 11, 19:00 CET

Presentation time: June 10, 08:50 CET

Venue: Birger Jarl Konferens, Birger Jarlsgatan 61 A, Stockholm, Sweden

For more information, please contact

Martin Jönsson, CEO

Tel: +46 707 86 94 43

martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.

Image Attachments

Martin Jönsson CEO AlzeCure Pharma

Attachments

AlzeCure Pharma to present at Stora Aktiedagarna in Stockholm on June 10